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Introduction
Gastric carcinoma (GC) is the second leading cause of cancer death throughout the world (1) . Global statistics showed that in 2008 alone, nearly 989,000 people were diagnosed with GC, and approximately 464,000 people died from this disease (2) .
Currently, GC prognosis is primarily determined based on the clinical data and pathological stages of patients at the time of diagnosis and treatment (3) . However, successful management of GC patients is still hampered by the lack of highly sensitive and specific biomarkers capable of predicting prognosis and likelihood of metastasis.
Epigenetic alterations, including aberrant DNA methylation changes, may play an important role in gastric carcinogenesis as indicated by the increased hypermethylation of tumor suppressor genes in GC patients (4) (5) (6) . Given their important functions in cancer initiation and progression, methylation changes are being investigated as potential biomarkers for the early detection of cancers, the prediction of cancer progression, and the prediction of chemotherapeutic sensitivity (7) .
Recent advances in high-throughput technologies have significantly expanded our capability of interrogating genome-wide DNA methylation changes in cancer (6, 8, 9) .
Methylated-CpG island amplification with microarray (MCAM) is one of the most powerful tools available for displaying differential methylation related to pathogenesis (10) . A number of DNA methylome studies have been reported in a variety of primary cancers, including GC. However, few studies have been conducted to vigorously validate the methylation changes of the candidate genes at the single molecule level in numerous tumor samples (6, 11) . Therefore, despite the long list of differentially methylated genes in GC patients, a promising DNA methylation biomarker has not yet reached to the clinical utility. Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- stages as described in the results section. In the validation cohort from Korea, 153 GC inpatients that received surgical treatment were selected from Seoul National University Hospital during 2004 with a follow-up of at least 3 years. Paraffin-embedded SM samples were used in the Korea study. The validation cohort from Japan included 78 GC inpatients that acquired surgical treatment between 1995 and 2002 with a follow-up of at least 5 years, as well as an additional 79 GC patients between 2010 and 2011 who did not have survival data. The SM samples were not available for these Japanese patients. GCs were classified as cardiac or non-cardiac in terms of location (14) .
Patients with pre-operative chemotherapy were not included in the discovery or independent validation cohorts. Normal/gastritis biopsies (NorG) from 56 outpatients at Peking University Cancer Hospital were used as the cancer-free controls.
Study design
The discovery patient cohort from Peking University Cancer Hospital consisted of 54 randomly selected patients with non-metastatic GCs and 54 matched patients with distant metastatic GCs. Among them, 8 paired GC and the corresponding SM samples from patients with or without distant and lymph metastasis were analyzed using MCAM on a customized Agilent promoter array. The clinical and histological features of these 8 patients can be found in Supplementary Table S1 . The remaining GC and SM samples from 100 patients were used for the characterization of 73 CGIs using DHPLC and bisulfite clone sequencing. The methylation states of the three most promising candidate CGIs were analyzed in three analogous independent validation cohorts from China (n=222), Japan (n=129), and Korea (n=153). The overall study design is outlined in Supplementary Fig. S1 . Genomic DNA was isolated using phenol/chloroform extraction. in humidified air with 5% CO 2 . These cell lines were tested and authenticated by Beijing JianLian Genes Technology Co., LTD before they were used in this study. STR patterns were analyzed using Goldeneye TM 20A STR Identifiler PCR Amplification Kit. Gene Genome-wide analysis of DNA methylation in GC tissues using MCAM Genomic DNA (2 g) from 8 pairs of fresh GC and SM samples was analyzed using the MCAM approach (10) . Briefly, genomic DNA was digested consecutively with SmaI and XmaI which cut unmethylated and methylated CCCGGG sites, respectively. The
XmaI digestion produces sticky ends that can be ligated to linkers, while SmaI digestion results in blunt ends that are unable to be ligated to linkers. The ligation-mediated PCR products from GC and SM samples were purified and labeled with Alexafluor647 or 555, respectively, using the Bioprime Plus Array CGH Indirect Genomic Labeling kit (Invitrogen, Carlsbad, CA) according to the manufacturers' instructions. The labeled DNA was co-hybridized to a custom designed Agilent Oligonucleotide Array, and the slides were washed and scanned as described previously (15) . Data was extracted
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Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- using the Feature Extraction Tool (Agilent Technologies, Santa Clara, CA) and exported for further analysis. The custom designed Agilent oligonucleotide array was designed using Agilent eArray service (https://earray.chem.agilent.com/earray). The array consisted of approximately 99,028 probes (44-60mers) that covered 29,879 in silico SmaI-digested DNA fragments (>60bp and <2000bp) in the human genome. The probes were tiled within each fragment with 100bp spacing. The methylation states of 6177 genes were determined using this custom methylation array.
Microarray data normalization and probe/gene selection
The raw array data was processed and normalized by the Beijing CO-FLY Bioinformatic Company. Background model adjustment was carried out using the minimum normalization algorithm. Systematic differences between arrays were normalized using the quantile method as described (16, 17) . The methylation array data, as well as the probe information, have been deposited into the Gene Expression Omnibus under accession number GSE47724.
The mean intensity of the normalized array hybridization (methylation) signal of each probe for sex-related chromosomes and autosomes in the SM samples from 4 males and 4 females ( Supplementary Fig.S2A -C) were analyzed. As expected, the intensities of 784 of 2390 X chromosome-probes (32.8%) were significantly higher in the female samples than the male samples (Student's t-test, P<0.05); in contrast, 35 of 87 Y chromosome-probes (40.2%) were significantly higher in the male samples when compared to the female samples. These sex-specific differences were only observed in 1250 of 96,550 (1.3%) probes in the 22 autosomes. These results confirmed that the quality of the normalized data is sufficient to differentiate sex-specific DNA methylation Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- and suitable for studying GC-or metastasis-related methylation changes.
The methylation signal ratio ([GC]/[SM]) was calculated for each array probe. The Student's paired t-test (P<0.01) was used to identify the differentially methylated probes between GC and SM samples from the 8 patients analyzed. The Mann-Whitney U-test (P<0.029) was used to identify the metastasis-specific differentially methylated probes between the 4 metastatic and 4 non-metastatic GC patients. The methylation ratio data including the adjusted P-values for each probe are included in the data file S1.
The difference between GC-related hypermethylated and hypomethylated probes was calculated for each sliding window (sequence or region) using 51 probe-matched fragments, which included the target probe along with 25 probes both upstream and downstream of the target. Probes near the centromeres and telomeres of each chromosome were not included due to the absence of the 25 upstream or downstream probes. The numerical differences for 99K probes were charted to display the detailed regional methylation trend (or net methylation signal) for the corresponding chromosome arm.
Identification of differentially methylated candidate genes
In order to identify GC and metastasis-specific differentially methylated candidate genes for further evaluation, the promoter and exon-1 regions were focused on due to their known inverse correlation to epigenetic repression of gene transcription. The differentially methylated probes in these regions were defined as the top-100 probes and used in hierarchical clustering analysis and preparation of a heatmap, when their Pvalues were less than 0.05, and their absolute mean difference-values were within the Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- top 100. Candidate genes were selected from these GC-or metastasis-related probes according to their function information in the public databases.
Hot-start PCR and DHPLC analysis
CpG-free universal primer sets and bisulfite-modified DNA (18) were used to amplify the genes of interest. The PCR reaction mixture (30 µl) included 20 ng DNA template, 0.15 mmol/L dNTP, 0.15 µmol/L of each primer, and 0.9 U of HotStart Taq DNA polymerase (Qiagen GmbH, Hilden, Germany). The PCR products were then analyzed quantitatively by DHPLC using the WAVE ® DNA Fragment Analysis System (12, 19) .
PCR products of hypermethylated and hypomethylated genes were separated using a 
MethyLight
The methylation states of GFRA1, SRF, and ZNF382 were determined using the MethyLight assays. Gene-specific probes labeled with 6FAM and TAMRA were employed to quantify the relative copy number of methylated alleles compared to the COL2A1 control (20) . The sequences of the primer set and gene-specific probes can be found in the supplementary materials and methods. were used to analyze the association between the percentage of methylated copies and the clinicopathological features. All statistical tests were two-sided, and P<0.05 was considered statistically significant. The cutoff value was calculated according to the receiver operating characteristic (ROC) curve using the percentage of methylated copies to predict GC metastasis. The log-rank test was used to compare survival time between groups. Cox-proportional hazards models were used to identify independent predictors of survival (month) with adjustment for relevant clinical covariates. Functional annotation of the differentially methylated regions was performed using EpiExplorer (21) .
Statistical analysis

Results
Genome-wide analysis of GC-related differential DNA methylation
In order to identify differentially methylated genes related to GC development and metastasis, genome-wide DNA methylation analysis was conducted in 8 pairs of GC and SM samples using the MCAM assay utilizing a 99K custom-designed Agilent Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR-13-3380 oligonucleotide microarray as described above (10) . Through this method, 9860 probes in 4047 genes were identified with significant methylation differences between the 8 GC Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- shown to harbor multiple long-range hypermethylated domains. In contrast, most regions in chromosomes 3, 4, 14, 15, and 18 were found to be more favorable to longrange hypomethylation (Fig. 1C) .
Genome-wide analysis of GC metastasis-related differential DNA methylation
Among the 8 pairs of GC and SM samples analysed, half were metastatic GCs and the other half were sex-, age-, location-, and differentiation-matched non-metastatic control GCs (Supplementary Table S1 ). The MCAM analysis identified 8553 probes that were differentially methylated between the metastatic and non-metastatic GC groups (Mann-Whitney U-test, P<0.029). Among these metastasis-related candidate probes, 623 probes corresponded to 480 genes that overlapped with the GC-related genes identified above. A heatmap displaying the top 100 metastasis-related, differentially methylated probes is provided in Fig. 1D .
Identification in 15 GC-related aberrantly methylated genes
From the list of differentially methylated CGIs, 63 candidate genes were selected for further analysis based on their known functions and statistical significance of differential methylation signals between metastatic and non-metastatic GCs or between GCs and SMs(Supplementary Table S2 ). Ten known tumor-related genes that were not included in the oligonucleotide array were also selected as complementary and control genes for the validation study. The CGIs of these 73 genes were amplified using CpG-free primer sets. The bisulfite-PCR products were then analyzed using DHPLC to quantify the methylation levels of these CGIs in the 8 paired GC and SM samples ( suggest that hypermethylation of these 11 genes may play significant roles in GC development. Furthermore, the GC samples showed a significantly higher percentage of hypermethylated CDKN2A and GFRA1 (Ps<0.050) and significantly lower levels of methylation in ELK1 and SIGIRR when compared to the SM samples.
The positive rate of methylation in CDKN2A and PSMD10 was significantly higher in the GC and SM samples than was seen in the NorG samples. In contrast, the positiverate and proportion of methylated ELK1 and GFRA1 in the NorG samples were strikingly higher than in the GC and SM samples, indicating that hypomethylation of these genes occurs in gastric carcinogenesis as field effects. Furthermore, the positive rates of BNIP3, KCNH1, and ZNF382 methylation in the GC samples were more than 3-times higher than the SM and NorG samples (29% vs. 7~4%, 42% vs. 4~14%, and 69% vs. 18~23%, respectively). Based on this information, these genes are most likely involved in GC-specific methylation changes.
The methylation states of these CGIs were further confirmed using traditional bisulfite sequencing. The bisulfite sequencing results were consistently in agreement with the DHPLC analysis ( Fig. 2B and Supplementary Fig. S3 ). In addition, quantitative MethyLight assays using fresh or formalin-fixed paraffin-embedded tissue samples further validated the DHPLC results (Supplementary Fig. S4A ; Spearman test, P<0.020).
To understand if methylation changes in these CGIs affect gene expression, the mRNA levels of SRF, ZNF382, and GFRA1 were analyzed in matched tissue samples using quantitative RT-PCR. The qRT-PCR results showed that mRNA expression of all three genes was inversely correlated with the prevalence of methylation in their CGIs (Supplementary Fig. S4B ; Spearman test, P<0.050).
Confirmation of GC metastasis-related DNA methylation markers
Among the above 48 pairs of GC and SM samples, 24 pairs were from patients with lymphatic and distant metastasis, and 24 pairs were from sex-, age-, location-, and GC differentiation grade-matched patients without metastasis. Thus, the methylation states of these 15 CGIs were further analyzed to determine if they are associated with GC metastasis. DHPLC results showed that the methylation states of the BMP3, GFRA1, SRF, and ZNF382 CGIs were significantly different between metastatic and nonmetastatic GC samples. The proportion of methylated BMP3 and GFRA1 was lower in the metastatic GC samples than the non-metastatic GC samples (median, 1.8% vs.
5.9%; 8.6% vs. 38.6%; Mann-Whitney U-test, Ps<0.040). The positive rate of SRF and ZNF382 methylation was also lower in the metastatic GC samples than the nonmetastatic GC samples (4% vs. 33%; 54% vs. 79%, P=0.020/0.066). Therefore, the relationship between GC metastasis and methylation of these four CGIs was tested in additional GC and SM samples obtained from Chinese patients (n=50~60). When these samples were taken together as a discovery cohort, the relationship between GC lymph/distant metastasis and the methylation changes in GFRA1, SRF, and ZNF382 Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- was statistically significant (Table 2) ; however, such an association was not observed for BMP3 (data not shown).
To investigate whether the methylation status of the three potential biomarkers mentioned above had an impact on overall survival, Kaplan-Meier analysis was performed on each gene individually. Results showed that the overall survival of GC patients with GFRA1 or ZNF382 methylation-high (cut-off value: percentage of methylated copies >26.4% for GFRA1 or 1.3% for ZNF382) or SRF methylation-positive was elongated when compared to methylation-low or methylation-negative patients in the discovery cohort (log-rank test, P=0.068, Fig. 3A ; P=0.010, Fig. 3B ; P=0.001, Fig.   3C , respectively). Sub-stratification analysis revealed that SRF methylation was only correlated with overall survival in patients with non-cardiac GCs (P<0.033) but not with cardiac GCs (P=0.146). Therefore, only non-cardiac GC patients were included in the survival analysis in the following SRF methylation validation cohorts.
The predictive value of these methylation markers for GC metastasis was further confirmed using three independent validation cohorts in China (n=222), Japan (n=129), and Korea (n=153). Because the proportion of both methylated and unmethylated alleles of CGIs can be quantitatively and simultaneously determined using DHPLC, this method was consistently used to detect the methylation levels within these CGIs in freshly-frozen gastric samples from Chinese and Japanese patients. However, MethyLight was used to analyze the paraffin-embedded samples from the Korean patients, as fresh samples were not available. Results from these cohorts showed that the methylation positive rates of GFRA1, SRF, and ZNF382 were inversely and significantly correlated with pTNM stage and lymph metastasis in all three cohorts (Table 3) . Kaplan-Meier analysis also showed that the overall survival of GC patients 
those without methylation of these two genes across all three validation cohorts ( Fig. 3A and 3B). However, correlation between ZNF382 methylation and overall survival of GC patients was not statistically significant in all three validation cohorts (Fig. 3C) 
Synergic analysis of three methylation markers
In order to investigate if a combination of the methylation markers (GFRA1, SRF, and ZNF382) has a synergistic effect on predicting GC metastasis, the merged data was reanalyzed in the above 4 patient cohorts. As expected, the number of patients with one or more methylated genes among the three-gene panel was significantly decreased in GC samples with lymph/distant metastasis (Fig. 3D left; linear-trend test, P<0.00001; one gene vs. two genes, P=0.046). The sensitivity and specificity of 2~3 positivemethylation changes of 3 genes for detection of non-metastatic GCs were 60% and 67%, respectively. The positive and negative predictive values were 57% and 69%. In addition, multivariate analysis also showed that the number of combined methylation changes of GFRA1, SRF, and ZNF382 was an independent predictor of overall survival for GC patients (n=246) after adjusting for the pTNM stage, GC location, differentiation, vascular embolus, age, and sex (HR=0.734; 95%CI [0.562-0.958]) (Fig. 3D right) . The pTNM stage and GC location were also independent survival factors (HR=3.608; 95%CI 
GFRA1, SRF, and ZNF382 expression changes in gastric carcinogenesis
The protein expression of the three genes in the paired GC and SM samples in both regular tissue sections and tissue microarray (TMA) were analyzed using the IHC assay as described in the supplementary methods (22) . IHC analysis revealed that GFRA1 expression was predominantly observed in the cytoplasm of stromal cells, especially in Fig. S5A ). Among 38 pairs of IHC-informative cases, the proportion of GCs with strong GFRA1-staining was significantly higher than SMs (24/38 vs. 12/38, P<0.01). Among 28 pairs of informative cases, the proportion of GCs with strong ZNF382-staining in epithelial cells was lower than SMs (4/28 vs. 11/28, P<0.07) (Supplementary Fig. S5B ). Statistically significant association was not observed between GFRA1 (or ZNF382) staining and clinical parameters, such as invasion, lymph metastasis, embolus, differentiation, and overall survival. SRF-staining was only observed in the nucleus of some stromal fibroblasts and smooth muscle cells in both regular GC and SM sections ( Supplementary Fig. S5C ). Therefore, SRF expression was not further examined using TMA.
Discussion
Over a four-year period, a comprehensive epigenetic biomarker discovery and validation study involving over 500 patient samples from three large academic medical centers in China, Japan, and Korea had been conducted. The biomarker discovery effort started off with a genome-wide analysis of differentially methylated genes between metastatic and non-metastatic GCs in a small number of patient samples. The microarray-based methylation profiling identified a large number of GC-specific and metastasis-specific candidate genes that were differentially methylated. From the list of differentially methylated genes, a step-by-step elimination process identified a 15-gene panel associated with GC/metastasis-specific DNA methylation changes. The 15 genes were validated using multiple independent methods from a discovery cohort of GC patient samples. Finally, a methylation biomarker-set consisting of GFRA1, SRF, and ZNF382 was validated for the prediction of GC metastasis and patients' overall survival in four cohorts from China, Japan, and Korea. This novel epigenetic biomarker set may Author Manuscript Published OnlineFirst on July 9, 2014; DOI: 10.1158/1078-0432.CCR- be used in the decision making process for personalized post-operational therapy. To our knowledge, this is the first such study which specifically focuses on the metastasis of gastric cancer.
A large number of genome-wide DNA methylation studies have been reported for many different tumor types in recent years (6, 10, 11) . However, most of the studies failed to perform large-scale and in-depth follow-up studies to validate the candidate genes discovered through the genome-wide analyses. As a result, few methylation markers have been developed from the large number of DNA methylation studies published so far. The present study represents the most comprehensive and quantitative characterization of DNA methylation biomarkers in GC to date. Moreover, the three methylation biomarkers associated with GC metastasis and patients' survival were validated not only in multiple cohorts, but also in freshly frozen and paraffinembedded samples using several independent methods such as DHPLC and MethyLight. The vigorous testing performed in this study ensures the high reliability and feasibility of these novel biomarkers in different clinical settings.
It has been previously reported that 2,540 of 17,800 tested genes are differentially expressed between 80 pairs of GC and SM samples. Furthermore, it was found that there are four times as many upregulated genes in GCs than there are downregulated genes (1983 vs. 557; GSE27342) (23) . Therefore, the frequent DNA hypomethylation in the promoter and exon-1 regions of the GC methylome observed in this study may account for the prevalent increase in gene expression. In fact, an increasing number of studies have reported reactivation of proto-oncogenes by DNA hypomethylation in several cancers (24) (25) (26) . Long-range epigenetic silencing and large epigenetic structures have been reported in different cancers (27) (28) (29) . Differential long-range hypermethylation and hypomethylation trends may be related to cancer/tissue-specific DNA methylation (11, 30) . In the present study, it was found that chromosomes 7, 8, and 20 appeared more favorable for long-range hypermethylation (or amplification of methylated-regions). In contrast, chromosomes 3, 4, 14, 15, and 18 had an affinity for long-range hypomethylation (or deletion of methylated-regions). Further studies are warranted to determine which of these long-range hypermethylated and hypomethylated-regions are GC-specific changes and which are changes across cancer-types.
Most of the 15 aberrantly methylated genes identified in GCs are involved in cell proliferation, differentiation, apoptosis, adhesion, and embryonic development (Supplementary Table S2 ). Previous reports have demonstrated that silencing of BMP3, BNIP3, CDKN2A, HOXD10, TFPI2, and ZNF382 via methylation correlates with both the development and progression of cancers (12, 19, (31) (32) (33) (34) . Similar associations were also observed in GC samples used in the present study. Methylation changes of KCNH1, PSMD10, and SRF in cancer tissues have not previously been reported.
Furthermore, BNIP3, KCNH1, and ZNF382 methylation levels were more than 3-times higher in the GC samples than in SM and NorG samples. It is needed to study whether methylation of these genes may affect their expression states in gastric carcinogenesis.
In addition, though TBX5 and ELK1 methylation is not associated with GC metastasis, the overall survival of GC patients with methylated TBX5 or ELK1 was longer than those without methylation (P=0.017 or 0.003; data not shown). Because some methylation changes may occur in both GC and SM samples from cancer patients, more GC-related its link with cancer metastasis has not previously been reported. In the present study, it was found that the methylation status of GFRA1, SRF or ZNF382 was consistently and significantly associated with GC metastasis and patients' overall survival in multiple cohorts from different populations, suggesting that they may be used as potential biomarkers for predicting GC metastasis and prognosis. Most importantly, the combination of the three markers was not only identified as an independent survival factor, but also as a strong synergistic biomarker set helping to distinguish metastatic GCs from non-metastatic GCs. The TMA analysis of GFRA1 and ZNF382 from 40 GC patients failed to demonstrate statistically significant association of their protein expression with clinicopathological parameters and overall survival of these patients; however, up-regulation of GFRA1 protein and down-regulation of ZNF382 was indeed observed in the GCs compared to SMs, which is in agreement with hypo-and hypermethylation of GFRA1 and ZNF382 observed in GCs. Our results suggest that DNA methylation analysis mighty be a more suitable diagnostic tool than IHC for these genes.
To further prove the clinical utility of this marker panel on early prediction for GC metastasis, a prospective followup study among non-metastatic GC patients is being conducted.
In conclusion, through a comprehensive and collaborative epigenetic biomarker discovery effort, we have demonstrated that the DNA methylation changes of GFRA1, SRF, and ZNF382 were coordinately associated with GC metastasis and overall patient survival, and this three gene panel has potential to be used as a synergistic biomarker set capable of improving the prognosis and treatment for GC patients.
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Research. Distribution of the number of patients with methylation changes in one to three genes (GFRA1, SRF, and ZNF382) in metastatic and non-metastatic GC groups. The number of patients with one more differentially methylated genes in non-metastatic GCs was significantly higher than metastatic GCs (left chart). The more number of genes associates with differential methylation, the longer of overall survival of GC patients will be (right chart).
